A Game-Changer in Bladder Cancer: Enfortumab Vedotin Plus Pembrolizumab Surges Ahead of Chemotherapy in Landmark 2025 Study Istraživanja Medicina News Zdravlje A Game-Changer in Bladder Cancer: Enfortumab Vedotin Plus Pembrolizumab Surges Ahead of Chemotherapy in Landmark 2025 Study Martin Clarke 7 June 2025 Phase 3 trial confirms enfortumab vedotin plus pembrolizumab dramatically outperforms chemotherapy for advanced urothelial carcinoma. Read More Read more about A Game-Changer in Bladder Cancer: Enfortumab Vedotin Plus Pembrolizumab Surges Ahead of Chemotherapy in Landmark 2025 Study
